Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.
Using J774 macrophages, the intracellular activities of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) against Staphylococcus aureus (strain ATCC 25923) have been quantitatively assessed in a 24-h model. S. aureus was positively localized in phagolysosomes by confocal and electron microscopy, and extracellular growth was prevented with 0.5 mg of gentamicin/liter (1x MIC) in controls. When tested at extracellular concentrations equivalent to their maximum concentrations in human serum, all antibiotics except azithromycin caused a significant reduction of the postphagocytosis inoculum within 24 h, albeit to markedly different extents (telithromycin [2 mg/liter], 0.60 log; ciprofloxacin [4.3 mg/liter], 0.81 log; gentamicin [18 mg/liter], 1.21 log; moxifloxacin [4 mg/liter], 1.51 log; oritavancin [25 mg/liter], 3.49 log). Intracellular activities were not systematically related to drug accumulation (apparent cellular-to-extracellular concentration ratios in infected cells: ciprofloxacin, 3.2; gentamicin, 6.8; telithromycin, 8.7; moxifloxacin, 13.4; azithromycin, 50; oritavancin, 348). Intracellular activity was not directly correlated to extracellular activity as measured in broth. Conditions of pH 5 (i.e., mimicking that of phagolysosomes) markedly reduced the activity of gentamicin, azithromycin, and telithromycin (>or=32 x) and fairly extensively reduced that of ciprofloxacin and moxifloxacin (>or=4 x) but did not affect oritavancin activity. We conclude that the cellular accumulation of antibiotics is not the only parameter to take into account for intracellular activity but that local environmental conditions (such as pH) and other factors can also prove critical.
Seral
Cristina
C
Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, Brussels, Belgium.
Van Bambeke
Françoise
F
Tulkens
Paul M
PM
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology; D001372:Aza Compounds; D017963:Azithromycin / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D005839:Gentamicins / Q000494:pharmacology*; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D016403:Lymphoma, Large B-Cell, Diffuse; D008264:Macrophages / Q000382:microbiology* / Q000648:ultrastructure; D051379:Mice; D008826:Microbial Sensitivity Tests; D008854:Microscopy, Electron; D000077266:Moxifloxacin; D011804:Quinolines; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014407:Tumor Cells, Cultured; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D017963:Azithromycin; D002939:Ciprofloxacin; D024841:Fluoroquinolones; D005839:Gentamicins; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D000077266:Moxifloxacin; D011804:Quinolines; C100708:oritavancin; D014640:Vancomycin